ViiV Healthcare Limited

ViiV Healthcare is a global specialist pharmaceutical company dedicated exclusively to the research, development, and commercialization of medicines for the treatment and prevention of HIV/AIDS. Established as a joint venture, its mission is to ensure no person living with HIV is left behind and to work towards ending the HIV epidemic. The company's global headquarters are located in London, United Kingdom.

The company's portfolio encompasses a range of HIV medicines, including antiretroviral fixed-dose combinations, integrase strand transfer inhibitors (INSTIs), and long-acting injectable therapies. Key products include Apretude, Cabenuva, Dovato, Juluca, Tivicay, Triumeq, Rukobia, and Vocabria, among others, addressing both HIV treatment and prevention. ViiV Healthcare holds approximately 32% of the global HIV therapy market, positioning it as a significant player in the sector.

Deborah Waterhouse serves as the Chief Executive Officer, with David Redfern as Chairman. In early 2026, the company's ownership structure was streamlined, with Pfizer exiting its stake. GSK plc maintained its majority ownership at 78.3%, while Shionogi & Co., Ltd. increased its economic interest to 21.7%. Recent developments include promising 12-month interim results from the EMBRACE study for lotivibart, a long-acting HIV treatment, reported in February 2026. ViiV Healthcare also extended its voluntary licensing agreement with the Medicines Patent Pool for cabotegravir for long-acting HIV treatment in July 2025 and entered an agreement with the US government in April 2026 for Section 232 tariff relief.